Does Repatha Stop Heart Attacks?
Repatha (evolocumab) does not stop heart attacks outright—it lowers the risk of them occurring in certain high-risk patients by reducing LDL cholesterol levels. In the FOURIER trial, patients with cardiovascular disease on Repatha plus statins had a 20% relative risk reduction in major cardiovascular events, including heart attacks (3.4% vs. 4.6% absolute risk over 2.2 years).[1][2] It targets PCSK9 to boost LDL receptor activity, clearing more LDL from blood, but benefits vary by patient profile.
How Does Repatha Work to Lower Heart Attack Risk?
Repatha binds PCSK9 protein, preventing it from degrading LDL receptors on liver cells. This increases LDL uptake and clearance, dropping LDL-C by 50-70% in trials. Lower LDL slows atherosclerosis plaque buildup in arteries, reducing chances of plaque rupture that triggers heart attacks.[1][3]
Who Benefits Most from Repatha?
It's FDA-approved for adults with atherosclerotic cardiovascular disease (ASCVD) on max statin tolerance to cut heart attack, stroke, and cardiovascular death risk. Also for kids 10+ with familial hypercholesterolemia (HeFH), and adults with primary hyperlipidemia plus statins. Real-world data shows strongest risk reduction in those with LDL-C over 100 mg/dL at baseline.[2][4]
What Do Clinical Trials Show on Heart Attacks Specifically?
FOURIER (27,564 patients): Repatha cut myocardial infarction risk by 27% (HR 0.73; 95% CI 0.65-0.81). Absolute risk dropped from 4.6% to 3.2% over ~2 years.[1] ODYSSEY OUTCOMES (alirocumab, similar PCSK9 inhibitor) echoed this with 24% MI reduction post-ACS.[5] No trials show zero heart attacks—residual risk persists.
What Are Common Side Effects and Risks?
Injection-site reactions (5-10%), nasopharyngitis, and flu-like symptoms top the list. Rare: allergic reactions, neurocognitive effects like confusion (0.2%). No direct heart attack increase, but monitor LDL too low (<25 mg/dL) in some cases.[2][6] Long-term safety holds up to 5+ years.
How Does Repatha Compare to Statins or Other Options?
Statins like atorvastatin cut MI risk 20-30% via cholesterol and inflammation reduction; Repatha adds 20% on top when statins max out.[1][7] Vs. competitors: Praluent (alirocumab) matches efficacy; inclisiran (Leqvio) needs dosing every 6 months. Triple therapy (statin + ezetimibe + PCSK9) yields biggest LDL drops (60-80%).[3]
Cost and Access for Heart Attack Prevention
List price ~$5,800/month (US), but copay cards drop it to $5-25 for eligible insured. Medicare covers for ASCVD with LDL ≥70 mg/dL post-statin. Biosimilars unlikely soon—key patents expire 2034-2036 per DrugPatentWatch.com.[8][9]
Sources
[1]: NEJM - FOURIER Trial (2017)
[2]: FDA Repatha Label
[3]: Circulation - PCSK9 Mechanism Review (2020)
[4]: Amgen FOURIER Post-Hoc Analysis
[5]: NEJM - ODYSSEY OUTCOMES (2018)
[6]: Repatha Safety Data (Amgen)
[7]: Lancet - Statin Meta-Analysis (2010)
[8]: DrugPatentWatch.com - Evolocumab Patents
[9]: GoodRx - Repatha Pricing